05
Jan

Novartis’ copy of Amgen’s top-selling Neupogen matched up well with the original, FDA reviewers said, recommending what would be the first U.S. approval of a biologic knock-off.

…read more

Source: Novartis rolls toward FDA nod with a copy of Amgen’s Neupogen

    

0 No comments